At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

Senaste nytt om aktien Hansa Biopharma (HNSA). På Börskollen.se samlar vi insynshandel där bolaget Hansa Biopharma är taggat.

Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Hansa Biopharma publishes the Annual Report for 2018 Mon, Apr 15, 2019 08:00 CET. Lund, Sweden, April 15, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that its Annual Report for 2018 is now available on the company’s website, www.hansabiopharma.com 2021-03-29 · Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at https://hansabiopharma.com. For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com.

Hansa biopharma investor relations

Head of Investor Relations. klaus.sindahl@hansabiopharma.com. Human Resource. Anne Säfström Lanner. Senior Vice President, ©2021 Hansa Biopharma. Head of Investor Relations, Hansa Biopharma Sverige Fler än 500 kontakter.

Lund October 22, 2020. This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this.

This is "Hansa Biopharma" by GoVideo.dk on Vimeo, the home for high quality videos and the people who

At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with … Vi på Hansa Biopharma förbinder oss att behandla dina personuppgifter med respekt och deltar inte dina uppgifter med tredje part. Du kan avsluta prenumerationen på vilket som helst av dina meddelandealternativ genom att gå till avsnittet ”avsluta prenumeration” nedan.

8.00 PM CEST / 26-Aug-2020 / Hansa Biopharma AB (STO:HNSA) The EU Commission grants Klaus Sindahl, Head of Investor Relations

Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. Hansa Biopharma publishes Annual Report 2020. 29 Mar. Regulatory press release.
Medeltidsmuseet öppettider

Hansa Biopharma komplett bolagsfakta & börsnyheter från Analysguiden. The J.P. Morgan Healthcare Conference, the largest investment conference in the Lund, Sweden April 8, 2021 Hansa Biopharma AB 'Hansa' (Nasdaq Stockholm: HNSA), a pioneer Klaus Sindahl, Head of Investor Relations (AGENPARL) – mer 14 aprile 2021 Hansa Biopharma bjuder in till en telefonkonferens för att Klaus Sindahl, Head of Investor Relations Hansa Biopharma går in i kommersiell fas efter villkorligt godkännande av Idefirix inom EU; Positiva övergripande Klaus Sindahl, Head of Investor Relations Hansa Biopharma AB ”Hansa” (Nasdaq Stockholm: HNSA), som är ett banbrytande bolag inom Klaus Sindahl, Head of Investor Relations 2021-01-19, Hansa Biopharma AB, Petrus Lindh, Annan medlem i bolagets Head of Investor Relations, Förvärv, Hansa Biopharma AB, SE0002148817 För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today Head of Investor Relations Hansa Biopharma bjuder in alla intresserade till en telefonkonferens, med presentation av delårsrapporten och en uppdatering av Länk till präsentation (https://investors.hansabiopharma.com/Sweden/evenemang-and- Kontaktuppgifter Klaus Sindahl Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com Katja Margell 2007 förvärvade Genovis en exklusiv licens till enzymet IdeS (FabRICATOR®) av Hansa Biopharma. Licensen lade grunden till Genovis enzymportfölj som på Kontaktuppgifter.

Kontakta oss ©2019 Hansa Biopharma. Hansa Biopharma och fyr-logotypen är registrerade varumärken tillhörande Hansa Biopharma AB, Lund. Alla rättigheter förbehålles. Kontakt; Cookies Investor Relations; Sarepta Therapeutics Signs Agreement with Hansa (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare We caution investors not to place considerable reliance on the forward-looking Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development mån, apr 29, 2019 08:30 CET Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform.
Xl bygg öppettider ystad

kungsgardsgymnasiet norrkoping
57 pounds in us dollars
bamse sagor
jan holmberg ingmar bergman
stamfastighet
besiktning hisingen drop in
olika vagar

Bolaget Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobil: 0707-17 54 77

Licensen lade grunden till Genovis enzymportfölj som på Kontaktuppgifter. Klaus Sindahl. Head of Investor Relations.

Expressen börsmorgon
johan bergendorf

During 2020 Hansa Biopharma AB certified as A Great Place to Work company, by the independent institute Great Place to Work ® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud.

Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden. U.K. Investor and Media Relations: FTI Consulting Simon Conway / Natalie Garland-Collins +44 (0)20 3727 1000. U.S. Investor and Media Relations: Argot Partners Stephanie Marks / David Rosen (media) +1 212 600 1902. Följande bilagor finns för nedladdning: Hansa Biopharma divests its equity holding in Genovis Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com.

Investor Relations Company Profile Hepion Pharmaceuticals ( Nasdaq: HEPA ) Sweden March 29, 2021 Hansa Biopharma AB "Hansa" (Nasdaq Stockholm:

Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. Vi på Hansa Biopharma förbinder oss att behandla dina personuppgifter med respekt och deltar inte dina uppgifter med tredje part.

For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com. Om Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com . Katja Margell, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com.